Sat, Dec 20, 2014, 9:39 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • chevymalibu1966 chevymalibu1966 Nov 9, 2012 10:09 PM Flag

    for longs

    not sure if you knew this. posted 11/5/12

    S&P MAINTAINS BUY OPINION ON SHARES OF VERTEX PHARMACEUTICALS
    (S&P Capital IQ) Following VRTX's Q3 earnings report, we lower our net present value-based target price by $7 to $60, as Incivek sales continue to decline at a faster rate than we projected. Q3 adjusted breakeven results, vs. $0.56 EPS, including stock option costs, was below our $0.30 estimate, on lower revenues. We cut our '12 adjusted EPS view $0.64 to $0.75 EPS, and '13's by $1.41 to a $0.20 loss. While we see slowing Incivek sales eroding near-term profitability as VRTX proceeds with drug pipeline investments, we see a robust opportunity to expand its leading cystic fibrosis franchise.

 
VRTX
118.90+1.16(+0.99%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.